Short-term tolerability and dose toxicity evaluation of 177Lu-DOTATATE for advanced neuroendocrine tumors (NET)

被引：0
|
作者：
Plaza, Bonilla J. [1 ]
Lorca, Martinez A. [1 ]
Martinez, Navarro T. [1 ]
Hernandez, Azpeitia P. [1 ]
Alonso-Gordoa, T. [1 ]
Molina-Cerrillo, J. [1 ]
Diez, Orduna M. D. P. [1 ]
机构：
[1] Hosp Univ Ramon & Cajal, Madrid, Spain
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
prrt; 177lu; toxicity;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H04
引用
收藏
页码：137 / 137
页数：1
相关论文
共 50 条
  • [31] Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Alicja Puszkiel
    Mathilde Bauriaud-Mallet
    Roxane Bourgeois
    Lawrence Dierickx
    Frédéric Courbon
    Etienne Chatelut
    Clinical Pharmacokinetics, 2019, 58 : 213 - 222
  • [32] Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Puszkiel, Alicja
    Bauriaud-Mallet, Mathilde
    Bourgeois, Roxane
    Dierickx, Lawrence
    Courbon, Frederic
    Chatelut, Etienne
    CLINICAL PHARMACOKINETICS, 2019, 58 (02) : 213 - 222
  • [33] Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Gupta, Santosh K.
    Singla, Suhas
    Bal, Chandrasekhar
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (09) : 593 - 599
  • [34] Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
    Ilan, Ezgi
    Sandstrom, Mattias
    Wassberg, Cecilia
    Sundin, Anders
    Garske-Roman, Ulrike
    Eriksson, Barbro
    Granberg, Dan
    Lubberink, Mark
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 177 - 182
  • [35] Safety of 177Lu-DOTATATE in Patients With Advanced Neuroendocrine Tumors: Data From a US Expanded Access Program
    Allen-Auerbach, M.
    Wolin, E.
    Nassiri, V.
    Broberg, P.
    El-Haddad, G.
    PANCREAS, 2021, 50 (03) : 453 - 453
  • [36] Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study
    Ballal, Sanjana
    Yadav, Madhav P.
    Damle, Nishikant A.
    Sahoo, Ranjit K.
    Bal, Chandrasekhar
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (11) : E457 - E466
  • [37] Dosimetry of 177Lu-DOTATATE administered into neuroendocrine tumors - An initial experience from India
    Gupta, Santosh
    Meera, V
    Malhotra, A.
    Kumar, Prateek
    Bal, Chandersekhar
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [38] Predictive factors of persistent thrombocytopenia after 177Lu-DOTATATE in patients with neuroendocrine tumors
    Oziel-Taieb, S.
    Ferrara, R.
    Charrier, N.
    Maniry, J.
    Reichert, T.
    Brenot-Rossi, I
    Niccoli, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 213 - 213
  • [39] Salvage 177Lu-dotatate therapy in patients with progressive metastatic neuroendocrine tumors.
    Hoe, Hui Jing
    Wyld, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16212 - E16212
  • [40] Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors
    Zandee, Wouter T.
    Brabander, Tessa
    Blazevic, Anela
    Kam, Boen L. R.
    Teunissen, Jaap J. M.
    Feelders, Richard A.
    Hofland, Johannes
    de Herder, Wouter W.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (04): : 1336 - 1344
12345